Multiple sclerosis market to generate sales of $29.8 bn by 2030: GlobalData EP News Bureau Apr 19, 2023 Tolebrutinib is expected to be the leading BTK inhibitor by 2030, with forecasted sales of approximately $2.6B across the 7MM
